Everything below concerns Cold chain. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reconstitution is the process of dissolving a dried peptide in a suitable solvent. The choice of solvent depends on solubility, charge, and sequence; sterile water is common, while buffers or small amounts of organic solvent may be needed for hydrophobic peptides. Adding solvent gently down the vial wall and mixing by inversion or gentle swirling reduces foaming and shear. Vortexing or vigorous pipetting can denature some peptides or promote aggregation. The resulting solution should be visually inspected for particles, turbidity, and complete dissolution before use.
After reconstitution, solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. Aliquots should be labeled with peptide identity, concentration, solvent, and date, then stored at the temperature specified by the supplier or protocol. Many peptides tolerate -20 °C for short periods, while -80 °C is preferred for longer storage. Frost-free freezers are generally avoided because temperature fluctuations can stress samples. Aseptic technique and sterile filters reduce microbial contamination, though filtration can also remove aggregated material or bind some peptides.
Cold-chain shipping uses insulated containers, phase-change packs, and temperature indicators. Dry ice maintains -70 °C or lower but requires venting to avoid pressure buildup. Gel packs provide 2-8 °C for shorter transit. Upon arrival, recipients should record temperature indicators and transfer vials promptly to storage. Deviations from specified conditions should be documented and may require analytical re-check. The effect of a brief temperature excursion is peptide-specific and not always predictable from general rules.
Handling begins with receipt and inspection. Vials should be checked for damage, label integrity, and temperature history. Lyophilized peptides should be allowed to equilibrate to room temperature before opening to prevent condensation. Solutions should be prepared in a clean, calibrated environment using appropriate solvents. Personal protective equipment and containment reduce exposure and contamination. Documentation of lot number, date, and storage location supports traceability. The goal is to limit repeated temperature changes, moisture exposure, and microbial contamination.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Organic cosolvent may be needed for hydrophobic sequences |
| pH adjustment | Sequence-dependent | Test small volumes before preparing the full solution |
| Filtration | 0.22 µm sterile filter | Can remove particles but may bind or remove aggregates |
| Aliquot size | Single-use volume | Reduces repeated freeze-thaw cycles |
| Post-reconstitution storage | -20 °C to -80 °C | Follow supplier or protocol; avoid frost-free cycles |
After reconstitution, solutions are divided into single-use aliquots and stored at -80°C. Labels include peptide name, concentration, buffer composition, date, and lot number. Freeze-thaw cycles are minimized by thawing only the needed aliquot on ice or at room temperature. Some peptides benefit from the addition of a carrier protein, such as bovine serum albumin, or a cryoprotectant like glycerol to reduce adsorption to plastic. Glass vials with low-binding surfaces are preferred for dilute solutions. Shipping of frozen aliquots uses dry ice and insulated containers to maintain the cold chain.
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
Reconstitution introduces new risks because the peptide contacts solvent, air, and container surfaces. The chosen solvent should match the peptide's solubility profile, and buffer salts, pH, and ionic strength can affect dissolution and subsequent stability. Gentle mixing is preferred over vigorous vortexing, which can create interfaces and shear. If the solution is not clear, the cause may be incomplete dissolution, aggregation, or insoluble counter-ions rather than a simple concentration problem. Filtration is sometimes used, but filters can adsorb peptides and alter measured concentration.
Cold-chain practice relies on documented temperature ranges, calibrated monitoring, and minimized excursions. Shipments may use insulated boxes, phase-change materials, or dry ice, with data loggers to record conditions. Upon receipt, the recipient should verify the logger trace and place items into long-term storage promptly. Repeated warming and cooling during transfers can be more harmful than a single controlled excursion. For solutions, dividing material into single-use aliquots reduces the number of thawing and refreezing events and limits repeated opening of the same container.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
== External links == PiHKAL ("Phenethylamines I Have Known And Loved") by Alexander "Sasha" Shulgin (1991) DOx - PsychonautWiki Category: DOX - Tripsitter DOx (psychedelics) - Wikipedia Massviews Analysis (Wikipedia Page Views of Individual DOx Drugs)
=== Civilian === The main use of uranium in the civilian sector is to fuel nuclear power plants. One kilogram of uranium-235 can theoretically produce about 20 terajoules of energy (2×1013 joules), assuming complete fission; as much energy as 1.5 million kilograms (1,500 metric tonnes) of coal. Commercial nuclear power plants use fuel that is typically enriched to around 3% uranium-235. The CANDU and Magnox designs are the only commercial reactors capable of using unenriched uranium fuel. Fuel used for United States Navy reactors is typically highly enriched in uranium-235 (the exact values are classified). In a breeder reactor, uranium-238 can also be converted into plutonium-239 through the following reaction:
Carboxypeptidase E (CPE), also known as carboxypeptidase H (CPH) and enkephalin convertase, is an enzyme that in humans is encoded by the CPE gene. This enzyme catalyzes the release of C-terminal arginine or lysine residues from polypeptides. CPE is involved in the biosynthesis of most neuropeptides and peptide hormones. The production of neuropeptides and peptide hormones typically requires two sets of enzymes that cleave the peptide precursors, which are small proteins. First, proprotein convertases cut the precursor at specific sites to generate intermediates containing C-terminal basic residues (lysine and/or arginine). These intermediates are then cleaved by CPE to remove the basic residues. For some peptides, additional processing steps, such as C-terminal amidation, are subsequently required to generate the bioactive peptide, although for many peptides the action of the proprotein convertases and CPE is sufficient to produce the bioactive peptide.
The suicide of Albert Vögler on 14 April 1945 left the KWS without a president. The British chemist Bertie Blount was placed in charge of its affairs while the Allies decided what to do with it, and he decided to install Max Planck as an interim president. Now aged 87, Planck was in the small town of Rogätz, in an area that the Americans were preparing to hand over to the Soviet Union. The Dutch astronomer Gerard Kuiper from the Alsos Mission fetched Planck in a Jeep and brought him to Göttingen on 16 May. Planck wrote to Hahn, who was still in captivity in England, on 25 July, and informed Hahn that the directors of the KWS had voted to make him the next president, and asked if he would accept the position. Hahn did not receive the letter until September, and did not think he was a good choice, as he regarded himself as a poor negotiator, but his colleagues persuaded him to accept. After his return to Germany, he assumed the office on 1 April 1946.
Cesare Magati or Caesar Magatus (14 July 1577 – 9 September 1647) was an Italian physician and professor of medicine. He is known chiefly from his book De rara medicatione Vulnerum (1616) where he promoted the idea of natural processes in wound healing. In 1618 he joined the Capuchin Order and the next year he took on the name of Padre Liberato da Scandiano.
Sources: en.wikipedia.org
== Medical uses == Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It was approved on June 19, 1992, as a monotherapy and again in 1996 for use in combination with zidovudine (AZT). Using combinations of NRTIs was in practice prior to the second FDA approval and the triple drug combinations with dual NRTIs and a protease inhibitor (PI) were not far off by this time. In 1992 dideoxycytidine was listed as a specialty drug. The sale and distribution of zalcitabine has been discontinued since December 31, 2006.
Subsequent investigations to rule out any nefarious human action (such as stealing of 235U) confirmed the theory by finding isotope ratios of common fission products (or rather their stable daughter nuclides) in line with the values expected for fission but deviating from the values expected for non-fission derived samples of those elements.
== Further reading == Bateson, P. (2017) behavior, Development and Evolution. Open Book Publishers, Cambridge. ISBN 978-1-78374-250-9. Plomin, Robert; DeFries, John C.; Knopik, Valerie S.; Neiderhiser, Jenae M. (24 September 2012). Behavioral Genetics. Shaun Purcell (Appendix: Statistical Methods in Behavioral Genetics). Worth Publishers. ISBN 978-1-4292-4215-8. Retrieved 4 September 2013. Flint, Jonathan; Greenspan, Ralph J.; Kendler, Kenneth S. (28 January 2010). How Genes Influence Behavior. Oxford University Press. ISBN 978-0-19-955990-9.
=== Exogenous === The Na+/K+-ATPase can be pharmacologically modified by administering drugs exogenously. Its expression can also be modified through hormones such as triiodothyronine, a thyroid hormone. For instance, Na+/K+-ATPase found in the membrane of heart cells is an important target of cardiac glycosides (for example digoxin and ouabain), inotropic drugs used to improve heart performance by increasing its force of contraction. Muscle contraction is dependent on a 100- to 10,000-times-higher-than-resting intracellular Ca2+ concentration, which is caused by Ca2+ release from the muscle cells' sarcoplasmic reticulum. Immediately after muscle contraction, intracellular Ca2+ is quickly returned to its normal concentration by a carrier enzyme in the plasma membrane, and a calcium pump in sarcoplasmic reticulum, causing the muscle to relax. According to the Blaustein-hypothesis, this carrier enzyme (Na+/Ca2+ exchanger, NCX) uses the Na gradient generated by the Na+-K+ pump to remove Ca2+ from the intracellular space, hence slowing down the Na+-K+ pump results in a permanently elevated Ca2+ level in the muscle, which may be the mechanism of the long-term inotropic effect of cardiac glycosides such as digoxin. The problem with this hypothesis is that at pharmacological concentrations of digitalis, less than 5% of Na/K-ATPase molecules – specifically the α2 isoform in heart and arterial smooth muscle (Kd = 32 nM) – are inhibited, not enough to affect the intracellular concentration of Na+.
Bosentan inhibits endothelin-1 by blocking its action at the ETA and ETB receptors. Ambrisentan and sitaxsentan block endothelin-1 activity by selectively blocking the ETA receptor. Prostacyclins and prostacyclin agonists also cause vasodilation and also inhibit platelet aggregation. Epoprostenol, treprostinil and iloprost act as prostacyclin I2 (PGI2) analogues by binding to and activating the prostacyclin receptor to cause vasodilation. PGI2 activates adenylate cyclase to convert adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), cAMP inhibits proliferation of smooth muscle cells in the pulmonary artery walls, and causes relaxation of smooth muscle cells thus acting as a vasodilator. Selexipag acts as a PGI2 receptor agonist to also activate adenylate cyclase. Epoprostenol and treprostinil are given as continuous intravenous infusions. Treprostinil is also available as an inhaled form, as is iloprost. In those who have a sustained vasodilator response as determined during the right heart catheterization (approximately 10% of those with PAH are responders), long acting calcium channel blockers nifedipine, diltiazem or amlodipine are indicated. In disease that is refractory to medical therapy, an atrial septostomy may be used palliatively or as a bridge to lung transplantation.
Sources: en.wikipedia.org
It should first equilibrate to room temperature in a sealed container to prevent condensation on the cold contents. Opening too soon can introduce moisture and reduce stability, and the waiting period depends on vial size and packaging.
Hydrophobic peptides may require buffers, organic cosolvents, or a stepwise solvent approach. Small amounts of acetonitrile, methanol, or dimethyl sulfoxide are sometimes used, followed by dilution into aqueous buffer. The exact solvent system should be tested for the specific sequence.
Single-use aliquots limit freeze-thaw cycling, which can cause aggregation, precipitation, or loss of activity. They also reduce repeated opening of the same container and lower contamination risk. Labeling each aliquot supports traceability and consistent use.
No. Allowing the sealed vial to equilibrate to room temperature reduces condensation on the powder. Condensation can introduce moisture and promote degradation. Equilibration usually takes 15 to 30 minutes depending on vial size.